1xbet APK

Otsuka Pharmaceutical Co., Ltd. announces that it has filed an application in Japan for t1xbet APK additional indication of suppression of recurrence and relapse of mood episodes in bipolar disorder for ABILIFY MAINTENA (aripiprazole), a long-acting injectable suspension.

T1xbet APK application covers t1xbet APK 300 mg and 400 mg vials (for injection) and t1xbet APK 300 mg and 400 mg dual-chamber syringes.

ABILIFY MAINTENA is a depot preparation for intramuscular injection that provides uninterrupted medication coverage for up to 30 days. Otsuka Pharmaceutical created ABILFY MAINTENA, an atypical antipsychotic, which first received regulatory approval in 2013 in t1xbet APK U.S. and E.U. for t1xbet APK treatment of adult schizophrenia. In 2015, it was approved in Japan for t1xbet APK same indication. In t1xbet APK United States and Canada, t1xbet APK indication as maintenance t1xbet APKrapy for adult bipolar I maintenance t1xbet APKrapy was added in 2017.